Abstract
Converging neuroimaging, genetic, and post-mortem evidence highlights the fundamental role of synaptic density reductions in schizophrenia pathogenesis. However, the brain-wide spatial pattern of these alterations and the mechanisms underlying this patterning remain to be established. Here, using [11C]UCB-J radiotracer positron emission tomography (PET) imaging in individuals with schizophrenia (n=29) and healthy controls (n=93), we find a prominent and widespread pattern of lower synaptic density (0.58 < Cohen’s D < 1.47; pFWE<0.05) in patients. The left hemisphere is substantially more impacted than the right (Cohen’s D = 1.14; p < .001), with frontal, temporal, cingulate, thalamic, striatal and hippocampal areas particularly affected. Synaptic density alterations were not spatially aligned with gray matter alterations indexed using anatomical Magnetic Resonance Imaging. Lower synaptic density in the left hemisphere is associated with higher normative concentrations of GABAA/BZ, 5HT2A, mGluR5 and 5HT1B (𝑟𝑐𝑐𝑎 = .68; 𝑝 = .022). Simulation-based network diffusion models identified regions that may represent the initial sources of pathology, nominating left inferior frontal areas (𝑝𝐹𝖶𝐸 < .05) as potential foci from which synaptic pathology initiates and then propagates to structurally connected and molecularly similar areas. Overall, our findings provide in vivo evidence for widespread synaptic density deficits in schizophrenia that are left-lateralized, independent of gray matter alterations, aligned to specific neurochemical systems, and suggest that such synaptic pathology may propagate in a pattern consistent with axonal networks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by the National Institute on Drug Abuse (NIDA) grant R01 DA052454-03 (GAA), U54 AA027989 (KC), Dana Foundation David Mahoney program (RR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Yale University name gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Manuscript updated based on reviewer feedback. Analysis conducted in each hemisphere. CDM analysis removed.
Data Availability
All data produced in the present study may be based available upon request to the authors and ethical approval form appropriate an IRB.
